Abstract
Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro. Our study aimed to determine the frequency of mutations in four genes: EGFR, ERBB2, ERBB3 and ERBB4 and to investigate whether these mutations affect cellular behaviour and therapy response in vitro and outcomes after adjuvant trastuzumab-based therapy in clinical samples. We performed Agena MassArray analysis of 227 HER2+ breast cancer samples to identify the type and frequency of ERBB family mutations. Of these, two mutations, the somatic mutations ERBB4-V721I and ERBB4-S303F, were stably transfected into HCC1954 (PIK3CA mutant), HCC1569 (PIK3CA wildtype) and BT474 (PIK3CA mutant, ER positive) HER2+ breast cancer cell lines for functional in vitro experiments. A total of 12 somatic, likely deleterious mutations in the kinase and furin-like domains of the ERBB genes (3 EGFR, 1 ERBB2, 3 ERBB3, 5 ERBB4) were identified in 7% of HER2+ breast cancers, with ERBB4 the most frequently mutated gene. The ERBB4-V721I kinase domain mutation significantly increased 3D-colony formation in 3/3 cell lines, wher...Continue Reading
References
Jan 9, 1987·Science·D J SlamonW L McGuire
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Jun 26, 2003·Nucleic Acids Research·Pauline C Ng, Steven Henikoff
Oct 6, 2005·Proceedings of the National Academy of Sciences of the United States of America·Samuel BouyainDaniel J Leahy
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Mar 14, 2007·Cancer Cell·Cai-Hong YunMichael J Eck
May 9, 2007·Oncogene·M SundvallK Elenius
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten TroweTimothy S Heuer
Oct 28, 2008·Experimental Cell Research·Graham Carpenter, Hong-Jun Liao
Nov 18, 2008·Experimental Cell Research·Carl P BlobelMatthew Freeman
Dec 23, 2008·The Journal of Biological Chemistry·Denis TvorogovKlaus Elenius
Jul 25, 2009·Breast Cancer Research : BCR·Andrea SassenGero Brockhoff
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ana M Gonzalez-AnguloGabriel N Hortobagyi
May 27, 2010·Molecular Cancer Therapeutics·Neil A O'BrienDennis J Slamon
Jul 7, 2010·Oncogene·P M DasF E Jones
Jun 22, 2011·Clinical Proteomics·Bryan T HennessyGordon B Mills
Aug 22, 2012·Proceedings of the National Academy of Sciences of the United States of America·Heidi GreulichMatthew Meyerson
Oct 27, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Saori FujiwaraHirotaka Iwase
Dec 12, 2012·Cancer Discovery·Ron BoseMatthew J Ellis
Jan 8, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D TougeronL Karayan-Tapon
May 18, 2013·Cancer Cell·Bijay S JaiswalSomasekar Seshagiri
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brent N RexerCarlos L Arteaga
Sep 26, 2013·BMC Cancer·Anna MachleidtGero Brockhoff
Aug 26, 2014·Oncotarget·Siti Norasikin Mohd NafiAnthony Kong
Dec 2, 2014·Molecular Oncology·Delphine R BoulbesFrancisco J Esteva
Dec 22, 2014·Breast Cancer Research and Treatment·N ElsterA J Eustace
Dec 30, 2014·Breast Cancer Research and Treatment·N ElsterB T Hennessy
Jan 2, 2015·Human Molecular Genetics·Chengliang DongXiaoming Liu
Jan 16, 2015·Cell Cycle·Kaleigh CanfieldManabu Kurokawa
Feb 25, 2015·Haematologica·Nils WinkelmannJonathan C Strefford
Sep 4, 2015·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Gloria Yang-KolodjiDebu Tripathy
Feb 5, 2016·Cancer Chemotherapy and Pharmacology·Quan ZhangQunyou Tan
May 3, 2016·Cell Systems·Martin L MillerChris Sander
Feb 23, 2017·Molecular Cancer Therapeutics·Mei Hua JinDo-Youn Oh
Jul 29, 2017·Breast Cancer Research : BCR·Sinead ToomeyBryan T Hennessy